Tonix Pharmaceuticals

A video of Tonix Pharmaceuticals' presentation at NobleCon20, NOBLE Capital Markets 20th Annual Emerging Growth Equity Conference, from Tuesday, December 3, 2024, is available for replay under the IR Events tab of the Tonix Pharmaceuticals website here: https://bit.ly/3ZrLvZF It is also available as part of a complete catalog of presentations available at the NOBLE Capital Markets Conference website at www.nobleconference.com and on Channelchek, the investor portal created by NOBLE Capital Markets, at www.channelchek.com

Tonix Pharmaceuticals announces expansion of leadership team with two strategic hires. Bradley Raudabaugh, MBA, is joining as Vice President, Marketing, bringing over 25 years of marketing, sales and product planning experience to Tonix Pharmaceuticals. Errol Gould, Ph.D., will join as Vice President, Medical Affairs, with over 25 years of experience in R&D and medical affairs across a wide range of therapeutic areas, including fibromyalgia. Read more about the appointments here: https://bit.ly/3OB9T6b

Tonix Pharmaceuticals to participate in NobleCon20, NOBLE Capital Markets 20th Annual Emerging Growth Equity Conference, being held December 3-4 in Boca Raton, Fla. Jessica Morris, Chief Operating Officer of Tonix Pharmaceuticals, will present on Tuesday, December 3, 2024 at 12:00 p.m. ET. Learn more here: https://bit.ly/4fB1ATD

The first known case in the U.S. of clade I #mpox was confirmed in California according to the Centers for Disease Control and Prevention: https://bit.ly/3AZAbLV and https://bit.ly/48RYFU1 Tonix Pharmaceuticals is developing TNX-801 as a new, single-dose #mpox and #smallpox vaccine candidate that targets clade I and clade II #mpox and has shown to protect animals from lethal clade I #mpox challenge after a single dose: https://bit.ly/3ZkqAI3 Clade Ib #mpox is the cause of a global #mpox public health emergency that was declared by World Health Organization (WHO) in August 2024 and infects adults and children: https://bit.ly/40RqoSR This clade Ib #mpox is different from the clade IIb #mpox that caused the global outbreak in 2022 and is still circulating in the U.S. after infecting about 30,000 here, mostly gay men. Learn more about recent tolerability data of Tonix Pharmaceuticals's TNX-801 published in mSphere Journal here https://bit.ly/3ZjlvAV and here https://bit.ly/4eFdHh6

Tonix Pharmaceuticals to present at the 2024 Virtual Investor Summit on Thursday, November 21 at 10 a.m. ET. Read more here: https://bit.ly/40SoG3u Attendees can watch the live webcast here: https://bit.ly/3CwRww5

Tonix Pharmaceuticals presented data and analyses of TNX-102 SL treatment effects on fibromyalgia at the American College of Rheumatology (ACR) Convergence 2024 Annual Meeting, hosted by American College of Rheumatology. Learn more here: https://bit.ly/4eyDlEf

Tonix Pharmaceuticals announces peer-reviewed publication in mSphere Journal highlighting the tolerability of TNX-801, Tonix’s single-dose #mpox and smallpox vaccine candidate, in immune-compromised animals. Learn more here: https://bit.ly/3AJKMKS

Tonix Pharmaceuticals announces poster presentation on TNX-102 SL for fibromyalgia at the American College of Rheumatology (ACR) Convergence 2024 Annual Meeting on Sunday, November 17 at 10:30 a.m. ET in Washington, D.C., hosted by American College of Rheumatology. Learn more here: https://bit.ly/48R7EF9

Tonix Pharmaceuticals reports third quarter 2024 financial results and operational highlights. Read more here: https://bit.ly/4hYXFBM

Tonix Pharmaceuticals announces research agreement with Kenya Medical Research Institute (KEMRI) to design, plan and seek regulatory approval for a Phase I clinical study of TNX-801 for #mpox in Kenya. Read more here: https://bit.ly/4evv4kq